fashion -WSS

fashion

author：hotspot 2025-10-04 10:47:54 - browse：85

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Supreme Court mifepristone arguments center on docs' right to sue

States should stop sabotaging methadone treatment reform

Readout Newsletter: Merck, Vertex, and Viking updates

Nurses recount patients attacks

leisure time

fashion

focus

Moonlake's readout produced a cash windfall. Risks remain

Neuroscience’s long legacy of racism

Jerome Adams on the need for new antivirals for Covid

Abortion pill case raises question: who can sue the FDA?

Bright Health sells Medicare Advantage business to Molina

U.K. researchers warn about biases in medical devices, algorithms

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Abortion pill case raises question: who can sue the FDA?

Malaria cases in Florida and Texas: Here’s what you need to know

Steward Health Care has deal to sell doctor network to UnitedHealth

focus

Orchard's therapy for neuron disease in children wins FDA approval

Nurses recount patients attacks

Eliminate the waiting period for sterilization covered by Medicaid

Colonoscopy prep: Liquid

Plastic surgeons increase patient psychiatric screenings

Health AI adoption puts security, privacy startups on investors' radar

knowledge

hotspot

Wikipedia

hotspot